Cargando…
Early biochemical and radiographic response after one cycle of [(177)Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
PURPOSE: The aim of this study was to investigate very early radiographic PSMA PET response after one cycle of [(177)Lu]Lu-PSMA I&T radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) and to assess its role in predicting overall response and survival. METHODS: Th...
Autores principales: | Cytawa, Wojciech, Hendel, Robin, Tomasik, Bartłomiej, Weinzierl, Franz-Xaver, Bley, Thorsten, Jassem, Jacek, Schirbel, Andreas, Buck, Andreas K., Bundschuh, Ralph A., Hartrampf, Philipp E., Werner, Rudolf A., Lapa, Constantin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547638/ https://www.ncbi.nlm.nih.gov/pubmed/37474735 http://dx.doi.org/10.1007/s00259-023-06326-w |
Ejemplares similares
-
Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022) -
Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021) -
Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2022) -
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [(177)Lu]Lu-PSMA I&T during long-term follow-up
por: Hartrampf, Philipp E., et al.
Publicado: (2022) -
(177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
por: Bundschuh, Ralph A., et al.
Publicado: (2023)